News & Updates

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes and cancer results in significantly reduced mortality and hospitalizations relative to treatment with metformin, a study has shown.

Icotrokinra—the first and only targeted oral peptide designed to selectively block the interleukin-23 receptor (IL-23R), which has been approved for the treatment of plaque psoriasis—shows multiple favourable signals for the treatment of ulcerative colitis (UC), according to updated data from the phase IIb ANTHEM-UC study.

The use of dupilumab significantly delays disease relapse in patients with moderate-to-severe atopic dermatitis (AD) while having an acceptable safety profile, reports a study.